With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
Hosted on MSN1d
FDA lifts clinical hold on Amylyx’s Phase I ALS trialThis is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
Hundreds of thousands in monthly veteran benefits were stolen by New Bedford man. Here's what he was sentenced: ...
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback